Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CNS: drowsiness, fatigue.
CV: hypotension(IV).
GI: anorexia, diarrhea, nausea, vomiting, abdominal pain, stomatitis.
Derm: alopecia, pruritis, rash, urticaria.
Endo: sterility.
Hemat: anemia, leukopenia, thrombocytopenia.
Local: phlebitis at IV site.
Neuro: peripheral neuropathy.
Misc: ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS, fever.
Drug-Drug:
Testicular Neoplasms
Small-Cell Carcinoma of the Lung
Therapeutic Classification: antineoplastics
Pharmacologic Classification: podophyllotoxin derivatives
Absorption: Variably absorbed after oral administration (bioavailability ~50%). IV administration results in complete bioavailability.
Distribution: Rapidly distributed; poorly enters the CSF; probably crosses placenta; enters breast milk.
Protein Binding: 97%.
Metabolism/Excretion: Some metabolism by the liver with biliary excretion, 44% excreted in feces; 45% excreted unchanged by the kidneys.
Half-life: 4–11 hr.
(noted as effects on blood counts)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | unknown | 7–14 days (granulocytes) 9–16 days (platelets) | 20 days |
| IV | unknown | 7–14 days (granulocytes) 9–16 days (platelets) | 20 days |
NDC Code*